ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER).
Isolyte S in Dextrose 5% is a combination of electrolytes and dextrose. Dextrose provides caloric support and helps correct hypoglycemia. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) replenish fluid and electrolyte deficits, maintaining osmotic balance and acid-base homeostasis.
| Metabolism | Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle, releasing energy. Electrolytes are not metabolized; they are excreted renally or utilized in physiological processes. |
| Excretion | Renal elimination of water and electrolytes; dextrose is metabolized to CO2 and water, with <1% excreted unchanged in urine. Sodium and potassium are primarily excreted renally; acetate is metabolized to bicarbonate and excreted via lungs as CO2. |
| Half-life | Not applicable as a fixed pharmacokinetic parameter; dextrose half-life ~10 minutes (rapidly metabolized); electrolytes distribute and are cleared according to renal function. In patients with normal renal function, elimination half-life of water and electrolytes varies with hydration status and GFR. |
| Protein binding | None for dextrose, sodium, potassium, chloride; acetate minimally bound (<10% to albumin). |
| Volume of Distribution | Dextrose: ~0.2 L/kg (total body water); sodium: ~0.6 L/kg (extracellular fluid); potassium: ~0.6 L/kg (total body water but primarily intracellular). Vd corresponds to total body water for electrolyte components. |
| Bioavailability | 100% bioavailability via intravenous route. |
| Onset of Action | Intravenous: Immediate upon infusion; electrolyte effects begin within minutes; dextrose increases blood glucose within 1-2 minutes. |
| Duration of Action | Duration depends on infusion rate and renal function; electrolyte effects persist as long as infusion continues; dextrose effect lasts 15-30 minutes after cessation due to rapid clearance. |
Intravenous infusion; rate and volume determined by clinical condition, fluid and electrolyte requirements. Typical adult dose: 500-1000 mL as a single infusion, administered at a rate not exceeding 50 mL/kg/day.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in patients with anuria or severe renal impairment (eGFR < 30 mL/min/1.73 m²). For mild to moderate impairment (eGFR 30-89 mL/min/1.73 m²), monitor serum potassium and renal function; adjust infusion rate based on fluid and electrolyte status. |
| Liver impairment | No specific Child-Pugh based dose adjustment required. Use with caution in patients with severe hepatic impairment due to risk of fluid overload and electrolyte imbalances; monitor serum sodium and potassium. |
| Pediatric use | Intravenous infusion; dose based on weight and clinical condition. Typical rate: 5-20 mL/kg as a single dose, not to exceed 50 mL/kg/day. Adjust based on serum electrolyte levels and fluid balance. |
| Geriatric use | Use with caution due to increased risk of fluid overload, renal impairment, and electrolyte disturbances. Initiate at lower infusion rates and monitor renal function, serum electrolytes, and volume status closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | ISOLYTE S IN DEXTROSE 5% components are endogenous and excreted into breast milk in varying amounts. Dextrose is normal milk sugar; electrolytes are present in milk. No adverse effects on nursing infants are expected at therapeutic doses. M/P ratio: Not established for the combination; individual electrolytes and dextrose have high milk/plasma ratios but are physiologic. Use with caution. |
| Teratogenic Risk | ISOLYTE S IN DEXTROSE 5% is an electrolyte and carbohydrate solution. No specific teratogenic effects are associated with the components at therapeutic doses. However, during pregnancy, hyperglycemia or electrolyte imbalances may harm the fetus. First trimester: No known structural teratogenicity; second and third trimesters: Potential for fetal hyperglycemia, hyperinsulinemia, and electrolyte disturbances if maternal levels are not controlled. Use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hyperglycemia","Severe renal impairment (anuria or oliguria)","Hypersensitivity to any component","Patients with elevated lactate levels or lactic acidosis"]
| Precautions | ["Avoid in patients with hyperglycemia, severe renal impairment, or anuria","Monitor serum electrolytes and glucose levels during administration","Use with caution in patients with heart failure, renal disease, or those receiving corticosteroids","Risk of fluid overload and electrolyte imbalances","Do not administer unless solution is clear and container is intact"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, glucose, fluid balance, and renal function. Fetal monitoring: assess fetal heart rate and growth if prolonged infusion; avoid fluid overload and hyperglycemia. |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. Dextrose and electrolytes are physiologic; no impairment expected. |